Clobutinol

Clobutinol is a cough suppressant formerly distributed by Boehringer Ingelheim and its licensees under the names Lomisat and Silomat, by Bioter as Biotussin, and by Violani-Farmavigor as Pertoxil. It has been withdrawn from the market worldwide.

Clobutinol

Clinical data
Trade names	Biotussin, Lomisat, Pertoxil, Silomat
AHFS/Drugs.com	International Drug Names
Routes of administration	oral
ATC code	R05DB03 (WHO)
Legal status
Legal status	Withdrawn (EU)
Identifiers
IUPAC name (RS)-1-(4-chlorophenyl)-4-dimethylamino-2,3-dimethyl-butan-2-ol
CAS Number	14860-49-2 Y
PubChem CID	26937
DrugBank	DB09004 N
ChemSpider	25085 Y
UNII	1NY2IX043A
KEGG	D07716 Y
ChEMBL	ChEMBL1474889 N
CompTox Dashboard (EPA)	DTXSID2022838
ECHA InfoCard	100.035.373
Chemical and physical data
Formula	C14H22ClNO
Molar mass	255.79 g·mol−1
3D model (JSmol)	Interactive image
Chirality	Racemic mixture
SMILES Clc1ccc(cc1)CC(O)(C)C(C)CN(C)C
InChI InChI=1S/C14H22ClNO/c1-11(10-16(3)4)14(2,17)9-12-5-7-13(15)8-6-12/h5-8,11,17H,9-10H2,1-4H3 Y Key:KVHHQGIIZCJATJ-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Side effects and withdrawal

Side effects include drowsiness, dizziness, insomnia, nausea, vomiting, and abdominal discomfort.^[1] Studies in 2004 had indicated that clobutinol has the potential to prolong the QT interval.^[2] Clobutinol was in 2007 determined to cause cardiac arrhythmia in some patients.^[3]

Boehringer Ingelheim products containing clobutinol were voluntarily withdrawn from sale in Germany, and the rest of the world, on August 31, 2007.^[4]

The approval for Germany and the EU was revoked in 2008.^[5]

Prior to withdrawal, it was available throughout Europe and Central America, as well as in South Africa. Trade names include Biotussin, Lomisat (Spain), Pertoxil (Italy), and in most of the world, Silomat.^[6]

See also

• QT interval
• Long QT syndrome